Skip to main content
Stoke Therapeutics, Inc. logo

Stoke Therapeutics, Inc. — Investor Relations & Filings

Ticker · STOK ISIN · US86150R1077 LEI · 549300RD25SS2DIJHJ67 US Manufacturing
Open in API
Filings indexed 559 across all filing types
Latest filing 2022-05-10 Interim / Quarterly Rep…
Country US United States of America
Listing US STOK

About Stoke Therapeutics, Inc.

https://www.stoketherapeutics.com/

Stoke Therapeutics, Inc. is a biotechnology company focused on developing treatments for severe genetic diseases by addressing their underlying cause. The company utilizes its proprietary research platform, TANGO (Targeted Augmentation of Nuclear Gene Output), an RNA-based approach designed to restore protein levels. This technology works by upregulating protein expression from the healthy copy of a gene to compensate for a mutated or non-functioning copy, a mechanism particularly suited for haploinsufficient diseases. Stoke's lead investigational medicine, zorevunersen (STK-001), is in late-stage clinical development for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy. The company is also advancing its platform to treat other genetic conditions, including autosomal dominant optic atrophy (ADOA).

Recent filings

Filing Released Lang Actions
10-Q
Interim / Quarterly Report Q1 2022
2022-05-10 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 10, 2022, reporting the issuance of a press release announcing financial results for the quarter ended March 31, 2022. The text explicitly states that the press release is attached as Exhibit 99.1 and that the information is not filed as part of the report but is a press release. The document length is 3620 characters, which is relatively short and mainly serves as an announcement of the earnings release rather than the earnings release itself. According to the 'Menu vs Meal' rule, this is an announcement of a report (press release) rather than the report itself. Therefore, the correct classification is Earnings Release (ER), as the document announces quarterly financial results with key highlights, typical of an earnings release.
2022-05-10 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Schedule 14A proxy statement filed with the SEC, specifically labeled as 'Definitive Additional Materials' related to the 2022 Annual Meeting of Stoke Therapeutics, Inc. It includes voting instructions and details about director elections and auditor ratification. The content is focused on soliciting shareholder votes and providing information for the upcoming meeting, which aligns with the definition of Proxy Solicitation & Information Statement filings. The document length is under 5,000 characters and it is not a full report but materials related to a shareholder meeting vote solicitation. Therefore, the correct classification is PSI (Proxy Solicitation & Information Statement).
2022-04-26 English
DEF 14A
Proxy Solicitation & Information Statement
2022-04-26 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-17 English
FORM 4 SUBMISSION
Director's Dealing
2022-03-17 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.